atypical hemolytic uremic syndrome ahus also known complementmediated hemolytic uremic syndrome extremely rare lifethreatening progressive disease frequently genetic component cases effectively controlled interruption complement cascade particular monoclonal antibodies discussed later article proven efficacy many cases ahus usually caused chronic uncontrolled activation complement branch bodys immune system destroys removes foreign disease affects children adults characterized systemic thrombotic microangiopathy tma formation blood clots small blood vessels throughout body lead stroke heart attack kidney failure complement system activation may due mutations complement regulatory proteins factor h factor membrane cofactor occasionally due acquired neutralizing autoantibody inhibitors complement system components example h prior availability eculizumab soliris ravulizumab ultomiris estimated patients died developed endstage renal disease esrd despite use supportive care eg plasmapheresis first clinical bout ahus including subsequent relapses total approximately twothirds patients died required dialysis permanent renal damage within first year diagnosis despite plasma exchange plasma infusion clinical signs symptoms complementmediated tma include abdominal edema ahus often presents malaise fatigue well microangiopathic however severe abdominal pain bloody diarrhea laboratory tests may also reveal low levels platelets cells blood aid elevated lactate dehydrogenase ldh chemical released damaged cells therefore marker cellular decreased haptoglobin indicative breakdown red blood anemia low red blood cell countschistocytes damaged red blood elevated creatinine indicative kidney proteinuria indicative kidney patients ahus often present abrupt onset systemic signs symptoms acute kidney hypertension high blood myocardial infarction heart lung pancreatitis inflammation liver necrosis death liver cells encephalopathy brain failure neurologic cardiac kidney gastrointestinal gi organs well death occur unpredictably time either quickly following prolonged symptomatic asymptomatic disease example approximately patients ahus initially present proteinuria hematuria without acute kidney patients survive presenting signs symptoms endure chronic thrombotic inflammatory state puts many lifelong elevated risk sudden blood clotting kidney failure severe complications premature although many patients experience ahus single disease comorbidities common one study patients known family history ahus found coexisting disease condition comorbidities study included malignant hypertension tma history transplant tma associated pregnancy glomerulopathy systemic disease systemic lupus erythematosus sle progressive systemic sclerosis pss malignancy presence mutations complement regulatory proteins diseaseassociated variations genes encoding proteins ie patients comorbid conditions well patients ahus single disease suggests deviations normal genetic coding factors could result genetic predisposition tma individuals predisposed could ahus episodes precipitated one known disease triggers eg infection pregnancy surgery trauma well systemic diseases eg malignant hypertension sle cancercitation needed healthy individuals complement used attack foreign substances complement system highly regulated prevent damaging healthy tissues however patients ahus demonstrated chronic uncontrolled excessive activation complement result production antifactor h autoantibodies genetic mutations several complement regulatory proteins eg factor h factor membrane cofactor protein factor factor b complement results platelet activation damage endothelial cells cells line blood vessels white blood cell activation leading systemic tma manifests decreased platelet count hemolysis breakdown red blood cells damage multiple organs often ahus condition causes systemic tma fact makes differential diagnosis essential historically clinical diagnosis tmacausing diseases grouped broad category addition ahus included thrombotic thrombocytopenic purpura ttp shigatoxinproducing escherichia coli hemolytic uremic syndrome however understood although ahus stechus ttp similar clinical presentations distinct causes specific tests conducted differentiate diseases addition conditions cause tma secondary manifestation entities include systemic lupus erythematosus sle malignant hypertension progressive systemic sclerosis pss also known scleroderma pregnancyassociated hellp hemolysis liver dysfunction low platelets syndrome toxic drug reaction eg cocaine cyclosporine tacrolimus nevertheless ahus suspected patients presenting systemic tma appropriate diagnostic workup undertakencitation needed neurological kidneyrelated signs symptoms ahus overlap however unlike ahus ttp primarily autoimmune disorder presence inhibitory autoantibody results severe deficiency enzyme cleaves von willebrand factor vwf large protein involved blood clotting smaller ttp also genetic disorder characterized mutations gene leading severe deficiency congenital cause deficiency called upshawsch√ºlman lab test showing activity levels indicative similarly gastrointestinal gi signs symptoms ahus overlap stool samples patients diarrhea gi symptoms tested stec presence shigatoxin however positive identification shigatoxin required diagnose stechus rule ahus nevertheless appropriate clinical setting positive identification shigatoxin makes ahus ahus patients report mean timeline days overall diagnosis process first noticing symptoms receiving ahus diagnosis time report overall health state drops patients feeling good excellent feeling good poor halving health status index scale preillness although plasma exchangeinfusion pepi frequently used controlled trials safety efficacy ahus even though pepi often partially controls hematological manifestations ahus patients effectiveness demonstrated terms inducing total disease remission pepi associated significant safety risks including risk infection allergic reactions thrombosis loss vascular access poor quality importantly terminal complement activation shown chronically present surface platelets patients ahus appear clinically well receiving chronic guidelines issued european paediatric study group hus recommend rapid administration plasma exchange plasma infusion pepi intensively administered daily days reducing however american society apheresis offers weak recommendation plasma exchange treat ahus due low low quality evidence supporting use although patients experienced improvements red blood cell platelet counts plasma therapies generally result full eculizumab soliris appears useful atypical hemolytic uremic syndrome september us food drug administration fda approved orphan drug treat people approval based two small prospective trials people uk nice issued guidance use eculizumab treating ahus based five evidence sources including used randomised controlled trials identified prospective studies phase studies included patients different clinical baseline characteristics prospective studies lasted weeks however patients allowed continue treatment eculizumab extension studycitation needed ravulizumabcwvz ultomiris second generation monoclonal antibody ahus made alexion pharmaceuticals target ravulizumabcwvz eculizumab soliris changes structure antibody resulting longer serum half life therefore reduced dosing patients ahus esrd generally consigned lifelong dialysis carries survival rate infections accounting patients also remain ongoing risk nonkidney systemic complications diseasecitation needed despite history use patients ahus kidney transplantation address continued uncontrolled complement activation leads progressive systemic tma many patients ahus treated soliris ultomiris experience tma transplanted organ leading transplant patients undergone kidney transplantation still continued risk neurological gastrointestinal cardiovascular complications importantly premature mortality following kidney transplantation ongoing uncontrolled chronic complement activation associated ahus causes graft loss children adults well continued inflammatory tma insult combined liverkidney transplantation available patients due limited supply solid organs addition substantial nearterm risk mortality many physicians patients consider recent years transplant centers begun administer eculizumab patients tma receive kidney transplant strategy effective preventing tma recurrences patients using either eculizumab ravulizumab treatment ahus showed improvements kidney function even avoiding dialysis minimizing death markers disease activity blood also great improvement however available evidence substantial bias low quality therefore careful considerations futures studies treatment duration adverse outcomes risk disease recurrence associated prior use monoclonal antibodieseg soliris ultomiris patients ahus extremely poor prognosis among commonly identified ahus genetic mutation proportion patients experiencing negative outcomes eg need dialysis permanent kidney damage death within first year rose however sudden morbidity mortality could occur regardless mutational status ahus arise age cases first reported years oldest presentation one study age noted kidney transplantation ahus patients esrd rarely considered high incidence graft loss due tma recurrence transplanted organ consequently untreated ahus patients develop esrd undergo chronic dialysis associated significant morbidities worsened combined liverkidney transplantation attempted patients ahus although highrisk procedure mortality rate approaching prior availability usage treatments quality life poor patients ahus burdened fatigue renal complications hypertension neurological impairment gastrointestinal distress clotting site venous access worst cases pepi also reported associated significant safety risks highly disruptive patients lives due requirements extensive vascular access frequent since approval eculizumab soliris prognosis ahus patients improved risk relapse present discontinuation eculizumab treatment close monitoring ahus inherited acquired appear vary race gender geographic expected ultrarare disease data prevalence ahus extremely limited pediatric prevalence cases per million population documented one publication european hemolytic uremic syndrome hus registry involving pediatric ahus cases approximately percent genetically inherited atypical hemolytic uremic syndrome ahus also referred diarrheanegative hemolyticuremic syndrome patient advocacy groups helping determine research httpsenwikipediaorgwikiatypicalhemolyticuremicsyndrome